Calves were intranasally challenged with bovine herpesvirus 5 (BHV5) and followed for the development of viral infection, clinical encephalitis, histologic lesions in the brain, and viral sequences in the trigeminal ganglia. Calves that were previously vaccinated with bovine herepesvirus 1 (BHV1, n ϭ 4) or previously infected with BHV1 (n ϭ 5) or that had not been exposed to either virus (n ϭ 4) were compared. No calf developed signs of encephalitis, although all calves developed an infection as indicated by nasal secretion of BHV5 and seroconversion to the virus. Histologic lesions of encephalitis consisting of multifocal gliosis and perivascular cuffs of lymphocytes were observed in calves not previously exposed to BHV1. BHV5 sequences were amplified from the trigeminal ganglia of calves previously vaccinated and from calves not previously exposed to BHV1; calves sequentially challenged with BHV1 and later BHV5 had exclusively BHV1 sequences in their trigeminal ganglia. Administration of dexamethasone 28 days after BHV5 challenge did not influence clinical disease or histologic lesions in either previously unexposed calves (n ϭ 2) or previously immunized calves (n ϭ 2), although it did cause recrudescence of BHV5, as detected by nasal virus secretion.
Bovine herpesvirus 5 (BHV5) has been isolated from outbreaks of naturally occurring encephalitis 2, 4, 5, 10 and has experimentally induced the same disease. 3, 10 The prevalence of this virus is unknown because the disease is sporadic, with only 4 isolations of the virus in various parts of the United States. 1 Determination of the prevalence of this virus as well as the conditions under which it is able to induce disease is important because of the potential for fatal outbreaks of encephalitis in the United States and throughout the world. 2, 5, 10 Currently, serologic methods cannot distinguish between infections with BHV5 and bovine herpesvirus 1 (BHV1, commonly termed infectious bovine rhinotracheitis virus [IBRV]); 7 thus, isolated viruses must be analyzed using molecular techniques. 1 Because of the close genetic and antigenic relationship between BHV1 and BHV5, prior infection with or vaccination against BHV1 may protect against encephalitis caused by BHV5. The interaction between these 2 viruses, if any, in disease has not been investigated. In addition, the role of latency of BHV1 or BHV5 has not been investigated with respect to disease or protection against encephalitis.
A model has been developed to study BHV5-induced encephalitis in 1-2-day-old colostrum-deprived calves. Calves in this model develop a fulminant in-fection of the brain and exhibit rapidly progressing behavioral changes, leading to terminal recumbency. 3 Although this model works well to study the effects of BHV5 in very young calves, fatal encephalitis in the field is typically seen in calves Ն6 months of age. The present work summarizes the course of an experimental infection with BHV5 in 5-6-month-old calves, both with and without prior exposure to BHV1 and with or without dexamethasone treatment. Although these calves did not develop clinical signs of encephalitis, histopathologic evidence of encephalitis was found and viral DNA was detected in the trigeminal ganglia and brains of these animals using a sensitive polymerase chain reaction (PCR) test. 1
Materials and methods
Animals. Calves were obtained from a local dairy at the age of 3-4 mo, after utilizing a sensitive competitive enzyme-linked immunosorbent assay 15 to demonstrate the absence of antibodies to BHV1. Calves were maintained in isolation until challenged or vaccinated with virus.
Viruses. The virus strains used were the Cooper strain of BHV1 a and a field isolate of BHV5. 3, 9 Inoculation of calves. The following groups of 5-6-moold calves were intranasally challenged as described previously 1,3 with BHV5 and/or BHV1. Doses of viruses were 10 6 TCID 50 /ml BHV5, 1 ml in each nostril, and 7 ϫ 10 5 TCID 50 / ml BHV1, 1 ml in each nostril. Calves 1 and 2 were challenged with BHV5 on day 0. Calves 3 and 4 were challenged with BHV5 on day 0 and subsequently given daily intravenous injections of 20 mg dexamethasone b on days 28-32, as described previously. 3 This dosage regimen leads to the reactivation of BHV1 9,12,19 and BHV5. 3 Calves 5 and 6 were vaccinated intramuscularly with an attenuated modified live virus (MLV) vaccine containing BHV1 c and then challenged 48 days later with BHV5 on day 0. Calves 7 and 8 were vaccinated against BHV1 and then challenged 48 days later with BHV5 on day 0 and subsequently given dexamethasone on days 28-32. Calves 9, 10, 11, 12, and 13 were inoculated with virulent BHV1 and then challenged 36 days later with BHV5 on day 0. The BHV1-infected calves developed respiratory disease and were fully recovered 30 days later. Sample collection. Nasal swabs were collected as previously described 8 on postinfection days 2, 4, 6, 8, 10, and 14 and daily for 10 days posttreatment with dexamethasone. The nasal mucosa of both nostrils was scraped vigorously with a dacron-tip swab, which was then transferred to 2 ml of minimal essential medium and frozen at Ϫ70 C before titration. Trigeminal ganglia and brain tissue samples were collected immediately after euthanasia (day 28 or day 48), and stored at Ϫ70 C. Serum was collected on days 0, 7, 14, 28, 42, and 48 after BHV5 inoculation.
Sample analysis. Presence of infectious virus and viral DNA in nasal secretions and brain tissue was determined by quantitative virus isolation (VI) and by BHV1/5-specific PCR. 1 Areas of brain analyzed included anterior cerebral cortex, cerebellum, midbrain, thalamus, medulla oblongata, and trigeminal ganglia. Antibody titers to BHV1 and BHV5 were measured by the complement-enhanced serum neutralization technique. 15 Clinical observations and histopathologic examination. Clinical observations were performed as described previously. 3 Calves were monitored daily after BHV5 inoculation for body temperature, respiratory rate, and development of nasal exudate and twice daily for signs of neurologic disease, e.g., twitching, ataxia, circling, head pressing, nystagmus, seizures, and recumbency. Samples were collected for histopathologic examination from the same areas of the brain as used for VI. Tissues were fixed in 10% neutral buffered formalin, processed routinely, sectioned at 6 m, and stained with hematoxalin and eosin.
Results
Virus shedding. The amount of virus present in nasal secretions (VI) from each calf is shown in Tables 1-3. Shedding of BHV5 on days 1-14 after BHV5 inoculation differed among naive calves, calves previously vaccinated with BHV1, and calves that had been previously infected with virulent BHV1. The peak of viral shedding and the duration of shedding was lower for vaccinated calves than for naive calves ( Tables 1, 2 ). In addition, most calves that were previously infected with BHV1 (4 of 5) shed less BHV5 than either of the other groups; 1 previously infected calf (no. 12) shed no BHV5 ( Table 3) . Results of the PCR assay for BHV1/5 agreed with VI data; only BHV5 was shed postchallenge. The BHV1 vaccine virus, detectable with the BHV1-specific PCR (data not shown), was not shed in any of the vaccinated calves. The PCR assay was slightly more sensitive than VI.
Serologic viral titers. All calves seroconverted to BHV5 as expected (Table 4 ). Seroconversion to BHV1 was also observed because of the cross-reactive anti-gens on the viruses. In those calves vaccinated with BHV1 (nos. 5-8), there was a clear anamnestic response shown by titers to both viruses. Serologic titers in calves infected 36 days previously were high against both viruses and did not significantly change postchallenge (data not shown).
Latency of BHV1/5. All calves exhibited BHV5 viral sequences in their trigeminal ganglia, as determined by PCR, except for those calves that had been previously infected with BHV1. In these calves, BHV1 sequences were found in the trigeminal ganglia ( Table  3 ). The BHV1 vaccine was not detected in the trigeminal ganglia of any of the vaccinated calves. BHV1 and BHV5 sequences were never found together in the same animal.
Virus in other parts of the brain. BHV5 DNA was 
ND Ϫ ϩ * Calves 7, 8 were treated with dexamethasone on days 28-32. † DPI ϭ days postinoculation. Calves 5 and 6 were euthanized on day 28; calves 7 and 8 were euthanized on day 48. ‡ PCR performed using nasal secretions (DPI 0-14) of trigeminal ganglion samples (DPI 28 or 48). § ND ϭ not done. found in the medulla oblongata, cortex, and cerebellum by PCR from 1 naive calf at 28 days postinoculation. No infectious virus was isolated. No other calf was positive for BHV5 DNA or infectious virus in any of the brain tissues analyzed at 28 or 48 days postinoculation.
Histopathology. Mild encephalitis characterized by multifocal gliosis and perivascular cuffs of lymphocytes was present in naive calves inoculated with BHV5 (nos. 1, 2). Lesions were widely scattered in rostral cerebral cortex and medulla oblongata, particularly near the floor of the fourth ventricle. One calf also had moderate gliosis and perivascular cuffing in the pons (Fig. 1) . Similar lesions were also found in the brains of nonvaccinated calves given dexamethasone after BHV5 challenge (nos. 3, 4) , but the lesions did not appear to differ in severity or distribution. However, no lesions were observed in those calves previously vaccinated with BHV1, those previously infected with BHV1, or those vaccinated with BHV1 and given dexamethasone after BHV5 challenge.
Virus shedding from dexamethasone-treated calves. Treatment with dexamathasone after BHV5 challenge led to the reactivation and shedding of the virus in nasal secretions from 4 of 4 animals ( Table 5) .
Clinical signs. No clinical signs were observed in any animal. 1 . Medulla oblongata from a naive calf inoculated with BHV5 and euthanized on day 28. A distinct glial nodule (G) has formed in an area of neuronal loss and is typical of the histologic lesions in the naive BHV5-inoculated calves.
Discussion
Although BHV5 induced histologic lesions of encephalitis in 5-6-month-old calves, clinical disease was not observed. The mild lesions in these calves, in comparison with the severe encephalitis and death that occurs in neonatal calves, 3 suggest that the virus was controlled. This suggestion is supported by the lower viral titers found in the brains of these calves as compared with the titers in the brains of neonates. 3 Lesions were limited to glial nodules and perivascular inflammatory cell cuffs, in contrast to the severe encephalitis and acute neuronal necrosis observed in neonates. Vaccination with or immunity to BHV1 was protective against development of lesions in the brains of calves later exposed to BHV5. The higher serologic titers that developed in vaccinated calves as a result of the anamnestic immune response supports a role for crossprotective immunity. With respect to field infections, the widespread prevalence and immunity to BHV1 may be related to the relatively rare occurrence of BHV5.
BHV5 was not detected by PCR in the trigeminal ganglia from any of the calves previously infected with virulent BHV1 (calves 9-13). However, BHV1 was detected by PCR in the trigeminal ganglia of all of these calves. This suggests that a BHV1 infection that leads to latency may prevent the establishment of latency with BHV5 upon secondary infection. This hypothesis is in accordance with findings regarding another alphaherpesvirus, in which infection with 1 strain of herpes simplex virus (HSV) appears to prevent latency with a second genetically marked HSV strain. 6 However, this phenomenon is not general; dual latency has been demonstrated in studies where dexamethasone was administered following infection with 2 different BHV1 herpesvirus strains. 19 Although BHV5 was detected in nasal secretions of most of these previously infected calves, the virus titers were low, especially when compared with the titers seen in the other calves in the study. Antibodies that react with BHV1 are highly cross-reactive with BHV5. 7 Therefore, mucosal antibodies produced against BHV1 in these sequentially inoculated calves 
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may have been able to restrict BHV5 replication in the nasal passages. This finding suggests a role for the host immune response in preventing herpesvirus latency, as suggested previously for mucosal immunization against pseudorabiesvirus 11, 17 and BHV1. 13 Although vaccination with BHV1 did not prevent BHV5 latency, lack of histologic lesions in these calves indicates that the vaccine still protects against BHV5-induced neurologic disease. Vaccine strains are typically less virulent than wild-type strains, and this difference in virulence may account for differences in the behavior of BHV5. In addition to lowered virulence, vaccine strains induce lower antibody titers against BHV1 than do wild-type infections. Antibody neutralization may not be effective against BHV5 in this situation and may provide the opportunity for a more significant BHV5 infection, as indicated by higher virus titers in nasal secretions in vaccinated than in previously infected calves. It is commonly accepted that MLV BHV1 vaccines cannot prevent the establishment of latency with wild-type virus. 11, 14, 17, 19 The BHV1 intramuscular vaccine was not latent in trigeminal ganglia nor is it secreted from the nose of vaccinated calves (unpublished) . No other studies are available on whether this MLV establishes latency, although other attenuated herpesviruses, such as herpes simplex viruses 16 and attenuated BHV1, 14, 19 can become latent.
The prevalence of BHV1 12, 18 suggests that many calves have been exposed to it at a young age. As demonstrated in this study, infection with BHV1 may prevent significant infection with and latency of BHV5. Young unexposed calves or unvaccinated herds appear to be susceptible to infection with BHV5. 5, 9 If the calves survive the infection, BHV5 likely establishes latency and may then be reactivated under stressful conditions, allowing continued transmission of the virus. As demonstrated, vaccination against BHV1 may prevent BHV5-induced neurologic disease but does not prevent BHV5 latency. This mechanism is ideal for maintaining BHV5 in nature even when large numbers of cattle have been vaccinated against BHV1.
The effect of dexamethasone treatment on BHV5 infection was also investigated. Although virus shedding posttreatment demonstrated that BHV5 can be reactivated, dexamethasone given 1 month after challenge did not exacerbate the encephalitis or lead to clinical signs in previously vaccinated animals. Further experimentation with dexamethasone treatment and/or immunosuppression at various times after infection (without previous vaccination) is necessary to determine if these factors can play a role in disease.
